| Name | Title | Contact Details |
|---|
Goldfish Swim School was founded in 2005 by husband and wife team Chris and Jenny McCuiston. Chris and Jenny took a concept that they formulated with nearly two years of research, and cultivated a business that provides results in the learn-to-swim environment that you simply can`t find anywhere else. Their proprietary curriculum and systems were developed after traveling the country in search of the “best practices” to teach babies and young children how to swim. The first school, in Birmingham, Michigan, opened in 2006, and quickly saw success. Opening its doors with over 500 students at inception, Goldfish currently teaches more than 70,000 students per month across the franchise system. At the beginning of 2008, it made sense to begin the franchising process. As of early 2017, we are currently in the process of expanding franchise opportunities throughout the country and internationally, with over 80 schools open or in development in more than 23 states and Canada.
The Physicians' Assurance Corporation is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LifeMed Media, Inc is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Apalachee Center Inc is a Tallahassee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.